Is GAIT DISTURBANCE a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed GAIT DISTURBANCE.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 48 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported GAIT DISTURBANCE to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and GAIT DISTURBANCE. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause GAIT DISTURBANCE, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes GAIT DISTURBANCE. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if GAIT DISTURBANCE ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing GAIT DISTURBANCE: 48
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where GAIT DISTURBANCE is a reported side effect: 1.4419%

FDA reports of any drug causing GAIT DISTURBANCE : 45752
Average percentage for all medicated patients where GAIT DISTURBANCE is reported as a complication: 0.2867%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with GAIT DISTURBANCE:

TYSABRI (6440 patients)
AVONEX (4635 patients)
FOSAMAX (4049 patients)
ASPIRIN (3566 patients)
FORTEO (3063 patients)
LYRICA (2808 patients)
LIPITOR (2381 patients)
HUMIRA (1976 patients)
PREDNISONE (1738 patients)
ZOMETA (1721 patients)
ENBREL (1659 patients)
NEURONTIN (1654 patients)
LISINOPRIL (1435 patients)
SYNTHROID (1429 patients)
MAGNEVIST (1415 patients)
NEXIUM (1392 patients)
SIMVASTATIN (1386 patients)
SEROQUEL (1355 patients)
LASIX (1334 patients)
VITAMIN D (1287 patients)
COUMADIN (1255 patients)
CYMBALTA (1230 patients)
METHOTREXATE (1230 patients)
PLAVIX (1155 patients)
OMEPRAZOLE (1151 patients)
CRESTOR (1137 patients)
FOLIC ACID (1109 patients)
XANAX (1095 patients)
PRILOSEC (1077 patients)
ATENOLOL (1074 patients)
REBIF (1024 patients)
LEVAQUIN (1011 patients)
HYDROCHLOROTHIAZIDE (998 patients)
NORVASC (989 patients)
FUROSEMIDE (981 patients)
CELEBREX (981 patients)
VIOXX (974 patients)
ZOLOFT (974 patients)
AREDIA (966 patients)
GABAPENTIN (950 patients)
AMBIEN (949 patients)
ZOCOR (907 patients)
ACETAMINOPHEN (876 patients)
SANDOSTATIN LAR (866 patients)
CALCIUM (866 patients)
PROTONIX (863 patients)
OXYCONTIN (850 patients)
LEVOTHYROXINE SODIUM (846 patients)
LORAZEPAM (839 patients)
VICODIN (837 patients)
DIOVAN (823 patients)
BETASERON (817 patients)
PAXIL (809 patients)
PERCOCET (773 patients)
DIGOXIN (772 patients)
OMNISCAN (763 patients)
ALBUTEROL (759 patients)
CLONAZEPAM (755 patients)
TOPROL-XL (755 patients)
EFFEXOR (724 patients)
PREVACID (718 patients)
LEXAPRO (707 patients)
METOPROLOL TARTRATE (700 patients)
IBUPROFEN (700 patients)
LANTUS (700 patients)
ATIVAN (691 patients)
POTASSIUM CHLORIDE (676 patients)
REMICADE (674 patients)
BACLOFEN (661 patients)
METFORMIN HCL (658 patients)
ALENDRONATE SODIUM (643 patients)
WARFARIN SODIUM (626 patients)
ALLOPURINOL (606 patients)
KLONOPIN (599 patients)
ZYPREXA (599 patients)
CHANTIX (593 patients)
PREDNISONE TAB (591 patients)
DIAZEPAM (585 patients)
RISPERDAL (584 patients)
ADVAIR DISKUS 100/50 (577 patients)
DURAGESIC-100 (575 patients)
DEXAMETHASONE (560 patients)
OXYCODONE HCL (559 patients)
CALCIUM CARBONATE (557 patients)
PREMARIN (552 patients)
ALPRAZOLAM (545 patients)
PROZAC (541 patients)
EPOGEN (533 patients)
TRAMADOL HCL (532 patients)
ACTONEL (531 patients)
LORTAB (531 patients)
PREDNISOLONE (522 patients)
DECADRON (507 patients)
FOSAMAX PLUS D (504 patients)
GILENYA (504 patients)
MORPHINE (501 patients)
MULTI-VITAMINS (495 patients)
ZOFRAN (492 patients)
HUMALOG (488 patients)
ARIMIDEX (487 patients)
VALTREX (483 patients)
INSULIN (482 patients)
COREG (474 patients)
SPIRIVA (472 patients)
WELLBUTRIN (467 patients)
AMLODIPINE (467 patients)
LAMICTAL (466 patients)
VITAMIN B-12 (464 patients)
SINGULAIR (464 patients)
ASCORBIC ACID (451 patients)
NITROGLYCERIN (448 patients)
AVANDIA (446 patients)
VALIUM (444 patients)
BONIVA (438 patients)
ZETIA (435 patients)
FLEXERIL (433 patients)
MULTI-VITAMIN (432 patients)
TRAZODONE HCL (427 patients)
TEGRETOL (425 patients)
FENTANYL (424 patients)
ARICEPT (423 patients)
FISH OIL (423 patients)
RECLAST (421 patients)
CIPROFLOXACIN (416 patients)
ZANTAC (415 patients)
HEPARIN SODIUM INJECTION (407 patients)
CLONIDINE (406 patients)
COLACE (393 patients)
CELEXA (390 patients)
NAMENDA (389 patients)
VITAMIN E (385 patients)
KEPPRA (383 patients)
FEMARA (381 patients)
DILAUDID (378 patients)
CITALOPRAM HYDROBROMIDE (377 patients)
BENADRYL (373 patients)
CHEMOTHERAPEUTICS NOS (373 patients)
COZAAR (364 patients)
ALLEGRA (364 patients)
METOPROLOL (360 patients)
AMPYRA (359 patients)
GLEEVEC (358 patients)
AMOXICILLIN (358 patients)
AVELOX (358 patients)
GLIPIZIDE (357 patients)
BYETTA (351 patients)
AMITRIPTYLINE HCL (345 patients)
COMPAZINE (343 patients)
CLINDAMYCIN (342 patients)
ARANESP (341 patients)
FERROUS SULFATE TAB (341 patients)
LOVENOX (341 patients)
EFFEXOR XR (339 patients)
TAMOXIFEN CITRATE (338 patients)
FLOMAX (337 patients)
MORPHINE SULFATE (337 patients)
TOPAMAX (336 patients)
REVLIMID (336 patients)
TYLENOL (CAPLET) (335 patients)
DEPAKOTE (334 patients)
TYLENOL (332 patients)
LOPRESSOR (332 patients)
ZYRTEC (331 patients)
ABILIFY (330 patients)
RAMIPRIL (330 patients)
HYDROCODONE (329 patients)
OPTIMARK (328 patients)
EXELON (327 patients)
TAXOTERE (325 patients)
HYDROCODONE BITARTRATE (322 patients)
EXTAVIA (319 patients)
ENALAPRIL MALEATE (315 patients)
LEVOXYL (314 patients)
SPIRONOLACTONE (314 patients)
GLYBURIDE (314 patients)
DILANTIN (314 patients)
XELODA (312 patients)
REGLAN (309 patients)
VYTORIN (308 patients)
METOCLOPRAMIDE (307 patients)
MIRTAZAPINE (306 patients)
NEXAVAR (303 patients)
CARBAMAZEPINE (303 patients)
METOPROLOL SUCCINATE (302 patients)
CLOZARIL (301 patients)
ACTOS (296 patients)
REMERON (294 patients)
NAPROXEN (291 patients)
ULTRAM (290 patients)
PRAVASTATIN (289 patients)
POTASSIUM (287 patients)
METRONIDAZOLE (287 patients)
PANTOPRAZOLE (285 patients)
RANITIDINE (283 patients)
FLUCONAZOLE (280 patients)
ALL OTHER THERAPEUTIC PRODUCTS (280 patients)
SOMA (278 patients)
PROMETHAZINE (276 patients)
IRON (275 patients)
ZITHROMAX (273 patients)
RENAGEL (273 patients)
VOLTAREN (271 patients)
TEMAZEPAM (270 patients)
CLOZAPINE (268 patients)
MOTRIN (268 patients)
FAMOTIDINE (267 patients)
PAROXETINE HCL (264 patients)
METFORMIN (263 patients)
OXYCODONE (263 patients)
PERIDEX (262 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about GAIT DISTURBANCE and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.